Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial

Research output: Contribution to journalArticle

Abstract

The anti-PD-1 agent, nivolumab, has been approved both as monotherapy and in combination with ipilimumab for the treatment of unresectable or metastatic melanoma in the USA and European Union. Here we present the case of a patient with treatment-naive, metastatic mucosal melanoma and baseline LDH approximately seven times the upper limit of normal. The patient was enrolled in a clinical trial (CheckMate 066) and achieved a partial response, followed by a durable complete response with nivolumab treatment. The patient’s LDH levels were documented in each cycle and dropped markedly within 2 months, when partial response to treatment was already evident. LDH levels remained low for the rest of follow-up, consistent with the ongoing complete response to treatment. The patient experienced only mild immune-related adverse events (grade 1–2), which included vitiligo and rash. This exceptional response suggests that patients with high LDH levels at baseline should be considered for nivolumab treatment. LDH levels, however, should not serve as a predictive marker of response to nivolumab. Moreover, this case suggests the need to identify patients who will achieve the greatest benefit from nivolumab monotherapy.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalCancer Immunology, Immunotherapy
DOIs
Publication statusPublished - Sep 7 2016

Fingerprint

L-Lactate Dehydrogenase
Melanoma
Therapeutics
Vitiligo
European Union
Exanthema
nivolumab
Clinical Trials

Keywords

  • CheckMate-066
  • Lactate dehydrogenase
  • Melanoma
  • Nivolumab
  • PD-1

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

@article{8b77e87bba6a497d98a735eb55d0a3f6,
title = "Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial",
abstract = "The anti-PD-1 agent, nivolumab, has been approved both as monotherapy and in combination with ipilimumab for the treatment of unresectable or metastatic melanoma in the USA and European Union. Here we present the case of a patient with treatment-naive, metastatic mucosal melanoma and baseline LDH approximately seven times the upper limit of normal. The patient was enrolled in a clinical trial (CheckMate 066) and achieved a partial response, followed by a durable complete response with nivolumab treatment. The patient’s LDH levels were documented in each cycle and dropped markedly within 2 months, when partial response to treatment was already evident. LDH levels remained low for the rest of follow-up, consistent with the ongoing complete response to treatment. The patient experienced only mild immune-related adverse events (grade 1–2), which included vitiligo and rash. This exceptional response suggests that patients with high LDH levels at baseline should be considered for nivolumab treatment. LDH levels, however, should not serve as a predictive marker of response to nivolumab. Moreover, this case suggests the need to identify patients who will achieve the greatest benefit from nivolumab monotherapy.",
keywords = "CheckMate-066, Lactate dehydrogenase, Melanoma, Nivolumab, PD-1",
author = "Ascierto, {Paolo A.} and Vito Vanella and Grimaldi, {Antonio Maria} and Festino Lucia and Marco Palla and Ester Simeone and Nicola Mozzillo",
year = "2016",
month = "9",
day = "7",
doi = "10.1007/s00262-016-1898-2",
language = "English",
pages = "1--6",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",

}

TY - JOUR

T1 - Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase

T2 - a case report from a phase III trial

AU - Ascierto, Paolo A.

AU - Vanella, Vito

AU - Grimaldi, Antonio Maria

AU - Lucia, Festino

AU - Palla, Marco

AU - Simeone, Ester

AU - Mozzillo, Nicola

PY - 2016/9/7

Y1 - 2016/9/7

N2 - The anti-PD-1 agent, nivolumab, has been approved both as monotherapy and in combination with ipilimumab for the treatment of unresectable or metastatic melanoma in the USA and European Union. Here we present the case of a patient with treatment-naive, metastatic mucosal melanoma and baseline LDH approximately seven times the upper limit of normal. The patient was enrolled in a clinical trial (CheckMate 066) and achieved a partial response, followed by a durable complete response with nivolumab treatment. The patient’s LDH levels were documented in each cycle and dropped markedly within 2 months, when partial response to treatment was already evident. LDH levels remained low for the rest of follow-up, consistent with the ongoing complete response to treatment. The patient experienced only mild immune-related adverse events (grade 1–2), which included vitiligo and rash. This exceptional response suggests that patients with high LDH levels at baseline should be considered for nivolumab treatment. LDH levels, however, should not serve as a predictive marker of response to nivolumab. Moreover, this case suggests the need to identify patients who will achieve the greatest benefit from nivolumab monotherapy.

AB - The anti-PD-1 agent, nivolumab, has been approved both as monotherapy and in combination with ipilimumab for the treatment of unresectable or metastatic melanoma in the USA and European Union. Here we present the case of a patient with treatment-naive, metastatic mucosal melanoma and baseline LDH approximately seven times the upper limit of normal. The patient was enrolled in a clinical trial (CheckMate 066) and achieved a partial response, followed by a durable complete response with nivolumab treatment. The patient’s LDH levels were documented in each cycle and dropped markedly within 2 months, when partial response to treatment was already evident. LDH levels remained low for the rest of follow-up, consistent with the ongoing complete response to treatment. The patient experienced only mild immune-related adverse events (grade 1–2), which included vitiligo and rash. This exceptional response suggests that patients with high LDH levels at baseline should be considered for nivolumab treatment. LDH levels, however, should not serve as a predictive marker of response to nivolumab. Moreover, this case suggests the need to identify patients who will achieve the greatest benefit from nivolumab monotherapy.

KW - CheckMate-066

KW - Lactate dehydrogenase

KW - Melanoma

KW - Nivolumab

KW - PD-1

UR - http://www.scopus.com/inward/record.url?scp=84986243177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84986243177&partnerID=8YFLogxK

U2 - 10.1007/s00262-016-1898-2

DO - 10.1007/s00262-016-1898-2

M3 - Article

AN - SCOPUS:84986243177

SP - 1

EP - 6

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

ER -